Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model

Circulation

Volumn 100, Issue 1, 1999, Pages 67-74

  Poston, Robert S ^a   Billingham, Margaret ^a   Hoyt, E Grant ^a   Pollard, Jeffrey ^a   Shorthouse, Randi ^a   Morris, Randall E ^a   Robbins, Robert C ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibodies; Coronary disease; Immunohistochemistry; Immunology; Transplantation

Indexed keywords

CYCLOSPORIN; METHYLPREDNISOLONE; RAPAMYCIN; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; GRAFT REJECTION; HEART TRANSPLANTATION; HISTOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; VASCULAR DISEASE;

EID: 0033529387     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.1.67     Document Type: Article

References (28)

1. Azuma H, Tilney N. Chronic graft rejection. Curr Opin Immunol. 1994; 6:770-776.
2. Kosek J, Hurley E, Lower R. Histopathology of orthotopic canine cardiac homografts. Lab Invest. 1968;19:97-102.
3. Alonso D, Starek P, Minick C. Studies on the pathogenesis of atheroarteriosclerosis induced in rabbit cardiac allografts by the synergy of graft rejection and hypercholesterolemia. Am J Pathol. 1977;87:415-420.
4. Cramer D, Quian S, Harnaha J. Cardiac transplantation in the rat, I: the effect of histocompatibility differences on graft arteriosclerosis. Transplantation. 1989;47:414-420.
5. Glysing-Jensen T, Raisanen A, Sayegh MH, Russell ME. Chronic blockade of CD28-B7 mediated T cell costimulation by CTLA4Ig reduces intimai thickening in MHC class I and II incompatible mouse heart allografts. Transplant. 1998;64:1641-1645.
6. Cao W, Mohacsi P, Shorthouse R, Pratt R, Morris R. Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis: inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. Transplantation. 1995;59:390-395.
7. Morris R, Cao W, Huang X, Shorthouse R, Pratt R. Rapamycin (sirolimus) inhibits vascular smooth muscle cell DNA synthesis in vitro and suppresses narrowing in arterial allografts and in balloon-injured carotid arteries: evidence that rapamycin antagonizes growth factor action on immune and nonimmune cells. Transplant Proc. 1995;27:430-431.
8. Koskinen PK, Lemstrom KB, Hayry PJ. How cyclosporine modifies histological and molecular events in the vascular wall during chronic rejection of rat cardiac allografts. Am J Pathol. 1995;146:972-980.
9. Meiser BM, Billingham ME, Morris RE. Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease [see comments]. Lancet. 1991;338: 1297-1298.
10. Adams DH, Russell ME, Hancock WW, Sayegh MH, Wyner LR, Karnovsky MJ. Chronic rejection in experimental cardiac transplantation: studies in the Lewis-F344 model. Immunol Rev. 1993;134:5-19.
11. Ono K, Lindsey ES. Improved technique of heart transplantation in rats. J Thorac Cardiovasc Surg. 1969;57:225-229.
12. Nisco SJ, Hissink RJ, Vriens PW, Hoyt EG, Reitz BA, Clayberger C. In vivo studies of the maintenance of peripheral transplant tolerance after cyclosporine: radiosensitive antigen-specific suppressor cells mediate lasting graft protection against primed effector cells. Transplantation. 1995;59:1444-1452.
13. Yeung AC, Davis SF, Hauptmann PJ. Incidence and progression of transplant coronary artery disease over 1 year: results of a multicenter trial with use of intravascular ultrasound. J Heart Lung Transplant. 1995;14:8215-8220.
14. Hosenpud JD, Bennett LE, Keck BM, Fiol B, Novick RJ. The registry of the International Society for Heart and Lung Transplantation: fourteenth official report-1997. J Heart Lung Transplant. 1997;16:691-712.
15. Gao S, Schroeder J, Alderman E, Hunt S, Valantine H, Stinson E. Prevalence of accelerated coronary artery disease in heart transplant survivors: comparison of cyclosporine and azathioprine regimens. Circulation. 1989;80(suppl 3):100-105.
16. Miller L, Kabashigawa J, Valantine H. The impact of cyclosporine dose and level on the development and progression of allograft coronary disease. J Heart Lung Transplant. 1995;14:S227-S234.
17. Schmid C, Heemann U, Azuma H, Tilney NL. Comparison of rapamycin, RS 61443, cyclosporine, and low-dose heparin as treatment for transplant vasculopathy in a rat model of chronic allograft rejection. Transplant Proc. 1995;27:438-439.
18. Paul LC, Davidoff A, Benediktsson H. Cardiac allograft atherosclerosis in the rat: the effect of histocompatibility factors, cyclosporine, and an angiotensin-converting enzyme inhibitor. Transplantation. 1994;57: 1767-1772.
19. Shears L, Pham S, Tzeng E, Kawaharada N, Billiar T. Cyclosporine inhibits inducible nitric oxide synthetase (iNOS) expression in aortic allografts: an etiology for allograft vasculopathy. Surg Forum. 1996;47:451-453.
20. Gregory CR, Huang X, Pratt RE, Morris RE. Treatment with rapamycin and mycophenolic acid reduces arterial intimai thickening produced by mechanical injury and allows endothelial replacement. Transplantation. 1995;59:655-661.
21. Handa N, Hatanaka M, Baumgartner WA. Late cyclosporine treatment ameliorates established coronary graft disease in rat allografts. Transplantation. 1993;56:535-540.
22. Forbes RD, Zheng SX, Gomersall M, Guttman RD. Irreversible chronic vascular rejection occurs only after development of advanced allograft vasculopathy: a comparative study of a rat cardiac allograft model using a retransplantation protocol. Transplantation. 1997;63: 743-749.
23. Pham SM, Shears LL, Kawaharada N, Seghal SN. High local production of nitric oxide as a possible mechanism by which rapamycin prevents transplant arteriosclerosis. Transplant Proc. 1998;30:953-954.
24. Rose ML. Antibody mediated rejection following cardiac transplantation. Transplant Rev. 1993;7:140-149.
25. Reed E, Hong B, Ho E, Harris P, Suci-Foca N. Monitoring of soluble HLA alloantigens and anti-HLA antibodies identifies heart allograft recipients at risk of transplant associated coronary artery disease. Transplantation. 1996;61:566-572.
26. Rose EA, Smith CR, Petrossian GA, Barr ML, Peemtsma K. Humoral immune responses after cardiac transplantation: correlation with fatal rejection and graft atherosclerosis. Surgery. 1989;106:203-208.
27. Russell PS, Chase CM, Colvin RB. Alloantibody-, and T cell-mediated immunity in the pathogenesis of transplant arteriosclerosis: lack of progression to sclerotic lesions in B cell-deficient mice. Transplantation. 1997 15;64:1531-1536.
28. Dunn MJ, Crisp SJ, Rose ML, Taylor PM, Yacoub MH. Anti-endothelial antibodies and coronary artery disease after cardiac transplantation. Lancet. 1992;339:1566-1570.